Abstract
Many patients with acute lymphoblastic leukemia (ALL) show relapse post-chemotherapy. Therefore, it is important to develop a human induced pluripotent stem cell (hiPSC) line from ALL cells to verify the pathophysiology. However, the low efficiency of the established reprogramming protocol has hampered the development of ALL hiPSC lines. Our recently reported novel reprogramming method, using human placenta-derived cell conditioned medium (hPCCM), offers a relatively higher efficiency in humanized conditions. Here, we generated an hiPSC line from ALL-derived CD34+ bone marrow cells, using hPCCM for reprogramming. This hiPSC line might be a useful model for studies on ALL.